FACCA 2025 Annual Consolidated Report
Prepared: Oct. 1, 2025

Executive Overview

The Reporting Period for this report reflects data provided for the Casey DeSantis Cancer Research Program allocation from FY23-24 to FY25-26.

The Florida Academic Cancer Center Alliance (FACCA), consisting of Moffitt Cancer Center (Moffitt), UF Health Cancer Center (UF Health), Sylvester Comprehensive Cancer Center at the University of Miami (UM Sylvester), and Mayo Clinic Comprehensive Cancer Center in Florida (Mayo Clinic in Florida), formed in 2014 to build collaborations that expedite innovation in the area of cancer research throughout the State of Florida and maximize state investments in biomedical technology and research.

A primary goal of the program at the time of creation was to provide support for UF Health and UM Sylvester to obtain National Cancer Institute (NCI) designation and for Moffitt to sustain NCI Comprehensive designation. As reported previously, UF Health Cancer Center obtained NCI designation in June 2023. UM Sylvester competitively renewed their designation in 2024, having first obtained designation in 2019. Moffitt will submit for their sixth competitive renewal in January 2025 to take effect in 2026. Mayo Clinic joined the program in 2024, as an NCI designated Comprehensive Cancer Center, the same year as their most recent competitive renewal. Thus, all FACCA members are NCI designated and recognized for significant and impactful research.

Since the last consolidated FACCA report in 2023, this extraordinary partnership has strengthened its efforts to advance cancer care, research, and education throughout the State of Florida. The foundation of this relationship is engaged collaboration among faculty and staff at the centers. Examples over the last three years include:

• Expansion of the program to include Mayo Clinic in Florida
• Treatment of 79,480 newly diagnosed patients combined across all four centers
• Accrued 31,942 patients combined to investigator-initiated interventional clinical studies
• Competed for $480.2 million (M) in peer-reviewed grant funding across all four centers
• Provided programming for 51,604 clinical and scientific trainees
• Published 7,046 peer-reviewed articles across the four centers, with 301 unique articles featuring at least
  two (2) FACCA centers
• Continued to invest in the FACCA Pilot Program which has resulted in 9 pilot awards ($1.35M investment)
  over the last 5 years that have generated $19.5M in extramural funding, 20 peer-reviewed publications, and
  2 patent applications, demonstrating a strong return
• Three collaborative retreats; January 2022, March 2023, and April 2024, fueling research collaborations and alignment
• Continuous and purposeful collaboration and communication between the four (4) Center Directors
• Monthly virtual meetings between the four (4) Center administrative teams and principal Administrators.

Moffitt Cancer Center

Moffitt’s designation by the NCI as a Comprehensive Cancer center was officially renewed on February 1, 2022, with the start of year 25 of funding for the Cancer Center Support Grant (CCSG). Over the last two years, Moffitt has continued its forward momentum in achieving or sustaining its efforts to contribute to the prevention and cure of cancer. Moffitt is well-positioned for a strong and successful renewal of the NCI CCSG.

The last two years have been focused clinically on expanding access within the community. A new ambulatory center, Moffitt SouthShore, opened in January 2025. Located on 9 acres in Ruskin, Moffitt SouthShore is a 75,000-ft2 facility home to 18 exam rooms and 10 bays strictly for blood draws, as well as a full radiology suite offering MRIs, CTs, ultrasounds, mammograms, PET scans and radiation oncology services. Clinical trials will also be offered at Moffitt SouthShore, bringing both clinical care and research closer to patients.

The first development of the 775-acre Speros regional biomedical park in Pasco County has made significant progress. Construction of another Moffitt-owned 100,000-ft2 ambulatory center is well underway on this campus, and this is scheduled to open in January 2026. Next door to this ambulatory center will be a state-of-the-art proton therapy center that will offer flash therapy; this is scheduled to open in the spring of 2026.

Finally, a 5-story, 250,000-ft2 cutting-edge Discovery & Innovation Center is under construction and scheduled to open in the spring of 2026. This new facility will ultimately house 55 laboratories for the following research disciplines: metabolism, bioengineering, drug discovery including facilities for chemistry, cancer biology, and tumor metastasis. The initial construction will build out 28 of the 55 laboratories. Florida’s investment has enabled Moffitt to recruit 23 research faculty at all ranks (FY24 and FY25) to support innovative research. Of these new recruits, Moffitt was able to promote both highly competitive trainees to faculty from its own pool of highly qualified trainees, successfully retaining scientific expertise in Florida, and successfully competed for top-tier scientists against established institutions including:

• Marcelo Bonini, PhD; Robert H. Lurie Comprehensive Cancer Center; Chicago, IL
• Renee Brady-Nicholls PhD; Moffitt Cancer Center; Tampa, FL
• Sylvia Crowder, PhD; Moffitt Cancer Center; Tampa, FL
• Michael Dunne, PhD; Harvard University; Cambridge, MA
• Jeremy Goecks, PhD; Oregon Health & Science; University Portland, OR
• Patrick Grogan, MD, PhD; University of Wisconsin; Madison, WI
• Rober Haile, DrPH; Cedars-Sinai Medical Center; Los Angeles, CA
• Megan Hitchins, PhD; Cedars-Sinai Medical Center; Los Angeles, CA
• Chang Jiang, PhD; Moffitt Cancer Center; Tampa, FL
• Lilit Karapetyan, MD; University of Pittsburgh; Pittsburgh, PA
• Karen Lu, MD; MD Anderson; Houston, TX
• Jorge Mansilla-Soto, PhD; Memorial Sloan Kettering Cancer Center; New York, NY
• Stuart Maudsley, PhD; University of Antwerp; Antwerp, Belgium
• Martina Molgora, MD; Washington University School of Medicine; St. Louis, MO
• Duy Nguyen, PhD; University of Florida; Gainesville, FL
• Fabiana Perna, MD, PhD; Indiana University; Indianapolis, IN
• Yoly Pina, MD; Moffitt Cancer Center; Tampa, FL
• Mark Robertson-Tessi, PhD; Moffitt Cancer Center; Tampa, FL
• Greg Sawyer, PhD; University of Florida; Gainesville, FL
• Alex Soupir, PhD; Moffitt Cancer Center; Tampa, FL
• Gilmer Valdes, PhD; University of California, San Francisco; San Francisco, CA
• Nathan Ward, PhD; Moffitt Cancer Center; Tampa, FL
• Vivien Yin, PhD; Mayo Clinic; Rochester, MN

As a reflection of the high-quality mentoring and supportive research environments at Moffitt, in 2024, 11 faculty were awarded their First R01 or R01 equivalent award, 23 applications were filed and 52 IND applications.

Notable appointments to research leadership positions include:

• Karen Lu, MD; Executive Vice President, Physician-in-Chief
• Heather Jim, PhD; Associate Center Director, Population Science
• Jeremy Goecks, PhD; Assistant Center Director, Research Informatics
• Tiffany Carson, PhD; Program Leader, Health Outcomes & Behavior
• Conor Lynch, PhD; Program Leader, Cancer Biology & Evolution, Chair, Department of Microenvironment & Metastasis
• Paulo Rodriguez, PhD; Program Leader, Immuno-Oncology; Chair, Department of Immunology
• Marcelo Bonini, PhD; Chair, Department of Metabolism and Physiology
• Greg Sawyer, PhD; Chair, Department of Bioengineering; Chief Bioengineering Officer
• Xuefeng Wang, PhD; Chair, Department of Biostatistics & Bioinformatics
• Gilmer Valdes, PhD; Vice Chair, Department of Machine Learning; Research Director, Clinical AI

UF Health Cancer Center

Through sustained investment from the State of Florida, the UF Health Cancer Center has achieved NCI designation and is actively advancing its strategic goal of becoming an NCI Comprehensive Cancer Center. This designation affirms the Center’s leadership in scientific discovery, patient care, and community impact. UF Health Cancer Center has earned national recognition by U.S. News & World Report for ranking in 7 adult specialties, 5 pediatric specialties and distinguished as high performing in 17 categories.

The Center continues to build its reputation for excellence across the cancer continuum. In 2022, it was reaccredited by the Commission on Cancer (CoC) and received initial accreditation for the UF Health Rectal Cancer Program through the CoC’s National Accreditation Program for Rectal Cancer. A virtual site visit for reaccreditation is scheduled for August 2025. In January 2025, the Center also achieved recertification through ASCO’s Quality Oncology Practice Initiative (QOPI), reinforcing its commitment to quality, evidence-based oncology care.

In alignment with its Accelerate 2030 strategic plan, the Center is enhancing statewide access to prevention and early detection services through its mobile outreach unit, which delivers bundled cancer screenings directly to communities. This innovative approach offers screening for breast, cervical, colorectal, and lung cancers — prioritizing underserved and rural populations that experience disproportionate cancer burdens. The mobile unit is also integrated into the Center’s catchment-focused research and community-engaged initiatives, helping identify barriers to care and drive actionable solutions.

The UF Health Cancer Center is also recognized for its leadership in data science and informatics, leveraging the university’s strengths in artificial intelligence, machine learning, and clinical research informatics to accelerate discovery and improve patient outcomes. The Center’s researchers are applying these capabilities across cancer
prevention, precision oncology, population health, and cancer disparities research—positioning the Center as a data-driven engine for innovation.

With 351 members across 69 departments in 12 of UF’s 16 colleges and the Florida Museum of Natural History, the UF Health Cancer Center continues to unite transdisciplinary expertise to address the cancer burden in Florida and beyond. Its focus on integrating scientific innovation, community engagement, and inclusive
excellence ensures meaningful progress toward comprehensive status and lasting impact on cancer outcomes statewide.

Faculty recruitment is an ongoing initiative and was recognized as essential for UF Health’s resubmission application to NCI in 2022. During the period of 2022-2024, state funding has been a critical resource in the successful recruitment of a total of 18 strategic faculty recruits from several states, including established NCI Designated Cancer Centers and Academic Medical Centers. Among the recent recruits include:

• John Ligon, MD; National Cancer Institute; Bethesda, MD
• Jordan Milner, MD; New York Medical College; Valhalla, NY
• Alex H. Yoon, PhD, MPH; University of Florida; Gainesville, FL
• Jason Butler, PhD; University of Florida; Gainesville, FL
• Jae Jeong Yang, PhD, MPH, Vanderbilt University Medical Center; Nashville, TN
• Shama D Karanth. PhD, University of Florida; Gainesville, FL
• Serendipity Z Rinonos, MD, PhD; University of California, Los Angeles; Los Angeles, CA
• Qianqian Song, PhD; Wake Forest School of Medicine; Winston-Salem, NC
• Zhipeng Li, PhD; University of California, Berkeley; Berkeley, CA
• Mohammed Gbadamosi, PhD; University of Florida; Gainesville, FL
• Xingui Liu, PhD; University of Dundee; United Kingdom
• David Iglesias, MD; University of Florida; Gainesville, FL
• Anna Y Khanna, MD; University of Florida; Gainesville, FL
• Leighton A Elliott, MD; Geisinger Medical Center; Danville, PA
• Gahyun Gim, MD; Wilmot Cancer Center; Rochester, NY
• Donna Zhang, PhD; University of Arizona; Tucson, AZ
• Ayman M Mukhtar, MD, MBBS, DABIM, FRCPC; University of Toronto; Toronto, Ontario
• Sulma Mohammed, DVM, PhD; Purdue University; West Lafayette, Indiana

UM Sylvester Comprehensive Cancer Center

Sylvester Comprehensive Cancer Center at the University of Miami (UM Sylvester), the only academic cancer center in South Florida, became the 71st NCI designated Cancer Center in July 2019. In 2023, UM Sylvester competitively renewed its designation, receiving a score of 21. The Center’s catchment area remains a primary driver of its clinical and research agenda, encompassing a four-county region (Miami-Dade, Broward, Monroe, and Palm Beach) that spans more than 10,000 square miles. Of Florida’s 23 million residents, more than 6.5 million comprise UM Sylvester’s unique catchment area which is poorer and older than that of the national average, providing UM Sylvester’s investigators with important opportunities to advance cancer research more quickly than other areas in the country.

UM Sylvester’s Office of Outreach and Engagement and its team of 10 community health workers routinely collaborate with community residents to understand emerging concerns and close gaps in cancer education and care through targeted outreach. Leveraging UM Sylvester’s Game Changer Vehicles, the community health workers offer testing, screening, and education in the community. UM Sylvester’s Community Advisory Committee (CAC) consists of leaders of local organizations, Federally Qualified Health Centers (FQHCs), faith based organizations, and civic and advocacy groups that serve key population sub-groups, such as the Miccosukee Tribe, and individuals either treated at UM Sylvester or its partner, Jackson Health System. The CAC formally reports to the UM Sylvester Director, Stephen D. Nimer, MD, to ensure that community input is heard at the highest levels of leadership and can appropriately inform strategic planning and investment.

For 13 years, Dr. Nimer has built an impressive core of cancer researchers and health professionals to best position UM Sylvester as a national leader in cancer research, with teams of outstanding scientists who conduct impactful, collaborative, and transdisciplinary research. UM Sylvester’s 449 cancer researchers (as of 12/31/24),
span 44 academic disciplines and four UM Sylvester Research Programs: Tumor Biology (TB), Cancer Epigenetics (CE), Translational & Clinical Oncology (TCO), and Cancer Control (CC). The four programs’ various interests, perspectives, and expertise advance UM Sylvester’s competency in addressing the cancer problem and responding to unique challenges within South Florida.

With the support from the State of Florida appropriation, UM Sylvester has made sustained investments in basic, clinical, translational, and population-based research, as well as in the infrastructure that enables this work. These investments have strengthened the center’s Research Programs, expanded shared resources, and enhanced clinical research services. As a result, UM Sylvester continues to play a critical role in the NCI network, leading multiple Experimental Therapeutics Clinical Trials Network (ETCTN) studies. These include a pediatric brain tumor study led by Dr. Macarena de la Fuente and a breast cancer trial led by Dr. Carmen Calfa which achieved the highest national enrollment. Based on this success, the NCI invited UM Sylvester to submit a competitive UM-1 supplement submission, which was approved—granting the Center full ETCTN membership. To date, 97 patients have been enrolled to these important paradigm-shifting studies.

In parallel, strategic investments in education, training, and team science have led to significant funding milestones. These include two new cancer-relevant T32 training grants funded during the reporting period, totaling $559K in annual direct costs. In 2022, UM Sylvester was awarded its second five-year multi-project $5 million Leukemia & Lymphoma Specialized Center of Research Program (LLS SCOR) grant, focused on the epigenetics of myeloid malignancies—an area of particular relevance to Florida’s aging population. This award supports eight UM Sylvester members and three outstanding collaborators from Memorial Sloan Kettering Cancer Center and Brigham and Women’s Hospital. In the same year, UM Sylvester researchers and a collaborator at Columbia University were also awarded a major NCI P01 grant focused on esophageal
adenocarcinoma.

These achievements underscore how targeted investments are enabling UM Sylvester researchers to lead innovative, collaborative science. For example, recognizing a major limitation in clinical DNA methylations, a multidisciplinary team of four researchers from UM Sylvester (one biostatistician, two translational scientists, and one academic clinician) developed a novel generative AI solution to improve data coverage and analysis.

Because the cost of whole-genome methods restricts most studies to just 3-15% of CpGs sites, the team created DiffuCpG, a generative AI diffusion model that reconstructs the methylome genome-wide from reducedrepresentation data sets. DiffuCpG addresses the pervasive challenge of missing data in high-throughput
methylation platforms and has demonstrated superior accuracy and stability across tissue types and technologies. This innovation significantly enhances the utility of epigenetic data in translational cancer research with the ultimate application of improving patient outcomes.

Finally, UM Sylvester has continued to invest in the FACCA Pilot Funding Program, a collaborative effort with Moffitt and UF Health. This program is already yielding important outcomes, including peer-reviewed publications and new external funding, as outlined below (see the FACCA Pilot Projects section).

Through the support of the State of Florida’s Casey DeSantis Cancer Research Program, the Center’s NCI designation, and the rising reputation of the quality of clinical care and research, UM Sylvester has successfully attracted exceptional physicians and investigators from premier institutions. Building on this momentum, the Center has prioritized the strategic recruitment of leadership talent to accelerate progress in research, education and training, and patient care. Among these efforts, in 2024, Dr. Damian Green joined as Chief of the Division of Transplantation & Cellular Therapy and Assistant Director of Translational Research, bringing his pioneering work in immunotherapy—particularly stem cell transplantation, CAR-T and antibody-based treatments for multiple myeloma and B-cell malignancies—to Florida. In this leadership role, Dr. Green oversees strategic direction, research mentorship, recruitment support, and financial stewardship, serving as a vital partner in advancing Sylvester’s clinical and scientific mission. In 2023, Dr. Aman Chauhan was recruited to lead Sylvester’s Neuroendocrine Tumor Program. He is a globally recognized expert advancing clinical trials,
radiopharmaceuticals, and precision medicine for rare neuroendocrine cancers. Dr. Bradley Gampel also joined Sylvester in 2023 to expand pediatric and adolescents/young adults (AYA) neuro-oncology efforts. He treats CNS tumor patients across all age groups and leads novel clinical trials in brain and spinal tumors as part of Sylvester’s Brain Tumor Initiative.

Over the reporting period, state appropriations supported the recruitment of 41 new faculty. Each new recruit brings expertise, grant funding, and/or clinical trials to the State of Florida.

• Nicholas Borja, MD; University of Miami, Miller School of Medicine; Miami, FL
• Tasleem Arif, PhD; Icahn School of Medicine; New York, NY
• Priscila Barreto, MD; University of Miami, Jackson Memorial Hospital; Miami, FL
• Defne Bayik-Watson, PhD; Cleveland Clinic; Cleveland, OH
• Jonathan Bell, MD; University of Miami, Miller School of Medicine; Miami, FL
• Markus Bredel, MD; University of Alabama; Tuscaloosa, AL
• John Burnett, PhD; City of Hope Duarte, CA
• Michele Ceccarelli, MsC; University of Naples; Naples, Italy
• Aman Chauhan, MD; University of Kentucky; Lexington, KY
• Austin Dosch, MD; Washington University; St. Louis, MO
• Julie Grossman, MD; University of Miami, Jackson Memorial Hospital; Miami, FL
• Antonio Iavarone, MD; Columbia University; New York, NY
• Jibran Durrani, MD; National Institute of Health; Bethesda, MD
• Marcella Kaddoura, MD; Mayo Clinic; Rochester, MN
• Morgan Freret, MD; Memorial Sloan Kettering Cancer Center; New York, NY
• Bradley Gampel, MD; Dana Farber Cancer Institute, Harvard Medical School; Boston, MA
• Anna Lasorella, MD; Columbia University; New York, NY
• Chiara La Tessa, PhD; University of Trento; Trento, Italy
• David Lombard, MD, PhD; University of Michigan; Ann Arbor, MI
• Rui Gong, PhD; Columbia University; New York, NY
• Damian Green, MD; Fred Hutchinson Cancer Center; Seattle, WA
• Yan Guo, PhD; University of New Mexico; Albuquerque, NM
• Ronald Hendrickson, PhD; Memorial Sloan Kettering Cancer Center; New York, NY
• Caitlin Hester, MD; MD Anderson Cancer Center; Houston, TX
• Surinder Kumar, PhD; University of Michigan; Ann Arbor, MI
• Kiran Kurmi, PhD; Harvard Medical School; Boston, MA
• Marina Kushnirsky, MD; Memorial Sloan Kettering Cancer Center; New York, NY
• Kevin Van der Jeught, PhD; Indiana University; Indianapolis, IN
• Sangeetha Venugopal, MD; MD Anderson Cancer Center; Houston, TX
• Xiao (Joan) Wang, MD, PhD; MD Anderson Cancer Center; Houston, TX
• Dionysios (Dennis) Watson, MD, PhD; Cleveland Clinic; Cleveland, OH
• Erik Williams, MD University of California, San Francisco; San Francisco, CA
• Abhishek Pandey, MD; University of Colorado School of Medicine; Aurora, CO
• Thomas Plate, MD; University of Miami, Miller School of Medicine; Miami, FL
• Danny Reinberg, MD, PhD; Howard Hughes Medical Institute; Chevy Chase, MD
• Martin Rivas, PhD; Weill Cornell Medical College; New York, NY
• Amanda Rivera, MD; Albert Einstein College of Medicine; Bronx, NY
• Nima Sharifi, MD; Case Comprehensive Cancer Center; Cleveland, OH
• Asaad Trabolsi, MD University of Miami, Miller School of Medicine; Miami, FL
• Lara Traeger, PhD; Harvard Medical School; Boston, MA
• Zhipeng Wang, PhD; Harvard University; Boston, MA

Recruitment at UM Sylvester has significantly enhanced the University’s cancer focus and overall scientific environment, fostering greater collaboration, multidisciplinary innovation, and success in securing competitive peer-reviewed funding—resulting in significant growth in UM Sylvester’s overall research portfolio.

Over the reporting period, UM Sylvester has also invested in its research facilities. Primarily funded through philanthropy, the Griffin Cancer Research Building (GCRB) opened its doors in Spring 2025. The new building will collocate scientists and physicians, promote team science, and facilitate bench to bedside discoveries.

Mayo Clinic Comprehensive Cancer Center in Florida

Mayo Clinic in Florida proudly serves as one of three integral sites of the NCI Designated Mayo Clinic Comprehensive Cancer Center (MCCCC), recognized for its national leadership in cancer research, education, and patient care. Through close collaboration with its sites in Phoenix, AZ and Rochester, MN, Mayo Clinic in Florida leverages the strengths of a unified, multi-state model to accelerate scientific discovery and bring transformative innovations to patients with cancer. This collective effort is guided by Cheryl L. Willman, M.D., Executive Director of Mayo Clinic Cancer Programs and Director of the MCCCC. A distinguished physicianscientist and visionary leader in oncology, Dr. Willman brings a deep commitment to advancing cancer care and ensuring that cutting-edge research directly benefits patients across the nation and around the world. Under her leadership, Mayo Clinic continues to strengthen its position as a global leader in comprehensive, patientcentered cancer care.

In alignment with this commitment, Mayo Clinic successfully completed its NCI site visit on February 25, 2025, reaffirming its dedication to excellence in cancer research and care as part of its ongoing NCI Comprehensive Cancer Center designation.

In 2023, Roxana S. Dronca, M.D., was appointed as the Site Deputy Director of the MCCCC in Florida. A distinguished medical oncologist at Mayo Clinic and the Director of the Cancer CARE Beyond Walls (CCBW) program, Dr. Dronca has brought visionary leadership to the forefront of cancer research and care. Under her guidance, Mayo Clinic in Florida is advancing groundbreaking research and elevating patient experience across multiple dimensions of cancer care. Mayo Clinic in Florida has championed efforts in transforming cancer care delivery by developing innovative, integrated, and patient-centric cancer care models through platform transformation, blending virtual, in-facility,
and home-based care throughout a patient’s cancer journey. A cornerstone of this initiative is the Cancer CARE Beyond Walls (CCBW) program. Launched as a proof-of-concept clinical pilot in April 2023, CCBW began by serving patients within a 30-mile radius of Mayo Clinic in Florida. Following its demonstrated success and feasibility, the next phase is expanding into Florida’s Panhandle, further advancing Mayo Clinic’s commitment to providing high-quality cancer care in Florida’s most underserved regions. CCBW focuses on capturing patientreported experiences and preferences for home versus in-clinic treatment, along with quality-of-life assessments, safety metrics, and healthcare utilization. By generating critical data to inform future models of home-based cancer care, CCBW has the potential to serve as a national blueprint for virtual oncology services, positioning Mayo Clinic as a leader in delivering transformative, patient-centered cancer treatment.

Mayo Clinic in Florida continues to expand its research infrastructure with the development of advanced biomanufacturing capabilities, enhanced imaging technologies, and the bringing the First Carbon Ion Facility in the Americas to the State of Florida – The Duan Family Building. The Duan Family Building is a 225,000 square foot state of the art facility that houses advanced imaging and treatment areas, three linear accelerators, two proton gantries, a fixed beam room, and the first carbon ion beam in the Americas. Purposefully designed to integrate carbon ion therapy, proton beam therapy, and conventional radiation therapy within a single location, the facility will provide patients with seamless access to the most advanced and comprehensive radiation treatment options available. These strategic investments significantly improve precision therapies, accelerate the availability of cutting-edge treatments, and provide new hope for patients with challenging cancer diagnoses.

Mayo Clinic in Florida continues to attract and support exceptional physicians and scientists. By providing resources for recruitment and long-term professional success, these efforts help establish Mayo Clinic as a leader in cancer research, fostering innovation and strengthening the impact of discoveries on patient care worldwide. Recent recruits include:

• Oluwaseun O. Akinduro, MD; Brown University; Providence, RI
• Albert N. Attia, MD; Vanderbilt University; Nashville, TN
• Anders Berglund, PhD; Moffitt Cancer Center; Tampa, FL
• Rishitha Bollam, MD; NYU Langone Health Fellow; New York, NY
• Victoria E. Clark, MD, PhD; MD Anderson Cancer Center; Houston, TX
• Christine A. Cordova, MD; Cleveland Clinic; Cleveland, OH
• Michelle F. DeLeon, MD; Einstein HC Network; Philadelphia, PA
• Loic P. Deleyrolle, PhD; University of Florida; Gainesville, FL
• Kunle I. Elegbede, MD, PhD; MD Anderson Cancer Center; Houston, TX
• Lauren E. Haydu, PhD; United States Air Force – Joint Base San Antonio; San Antonio, TX
• Adam L. Holtzman, MD; University of Florida Proton Therapy Institute; Gainesville, FL
• James W. Jakub, MD; Mayo Clinic Rochester; Rochester, MN
• Adam M. Kase, MD; Mayo Clinic Fellow; Jacksonville, FL
• Sungjune Kim, MD, PhD; Moffitt Cancer Center; Tampa, FL
• Daniel M. Koffler, MD; Northwell Health; Lake Success, NY
• Shenduo Li, MD, PhD; Mayo Clinic Fellow; Jacksonville, FL
• Bo Lu, PhD; University of Florida; Gainesville, FL
• Homan Mohammadi, MD; Dana Farber Cancer Institute; Boston, MA
• Conor D. O’Donnell, MB, BCh, BAO; Mayo Clinic Fellow; Rochester, MN
• Oluwadamilola T. Oladeru, MD, MBA; University of Florida; Gainesville, FL
• Chunjoo Park, PhD; University of Texas Southwestern Medical Hospital (UTSW); Dallas, TX
• Katherine Poruk, MD; Cancer Treatment Centers of America; Atlanta, GA
• Michael S. Rutenberg, MD, PhD; University of Florida Proton Therapy Institute; Gainesville, FL
• Deepak K. Shrestha, PhD; University of Texas Southwestern Medical Hospital (UTSW); Dallas, TX
• Michael D. Story, PhD; University of Texas Southwestern Medical Hospital (UTSW); Dallas, TX
• Jun Tan, PhD; University of Texas Southwestern Medical Hospital (UTSW); Dallas, TX
• Sridhar Yaddanapudi, PhD; Washington University in St. Louis; St. Louis, MO

Mayo Clinic in Florida is resolutely committed to advancing cancer education, research, and patient care by developing the next generation of biomedical researchers and healthcare professionals. Through initiatives like the Cancer Research Training and Education Coordination Office (CRTEC), led by Associate Director John A. Copland III, Ph.D., and the Science Program for the Advancement of Research Knowledge (SPARK), Mayo Clinic in Florida fosters early talent development by providing high-achieving students in Jacksonville with hands-on research experiences, mentorship, and leadership opportunities. SPARK continues to demonstrate remarkable success, with 7 of 9 scholars earning awards at the 2025 Florida State Science Fair, including SPARK’s firstever overall State Champion and three SPARK scholars advancing to the International Science Fair (ISEF) in Columbus, Ohio.

Three-Year Trends

Peer-reviewed funding

The four centers have sustained their peer-reviewed funding for direct costs for Reporting Periods 2023 to 2025. Together, the centers have been awarded over $480M to directly fund innovative cancer research and are primarily from NCI and other NIH institutes. (Fig. 1).

To provide better context, of the $147.4M in grants awarded to organizations in Florida from NCI FY2024 (the most recently completed NIH fiscal year), 85.4% of the funds were awarded to FACCA members (Fig. 2). These awards fund 346 research projects across the four centers and demonstrate significant leadership in conducting nationally
recognized cancer research in the State of Florida.

Based on NCI grants (FY24 Reporter data), Florida holds steady as the 14th highest funded state, the same rank as reported in 2023. As the nation’s 3rd most populous state, with the Casey DeSantis Cancer Research Program providing critical support and investment, the four FACCA institutions are best equipped to further increase cancer related grant funding to the State.

FACCA members were also highly successful in competing for the peer-reviewed Florida Biomedical research grant programs (Bankhead Coley, James & Esther King, and Live Like Bella). Of the 33 grants in FY24, FACCA members were awarded 26 of them (78.8%).

Moffitt Cancer Center

For 2025 reporting period, Moffitt’s overall peer-reviewed awards totaled $62.1M, which is up 28.8% from the last report ($48.2M). This represents 337 research projects being conducted by Moffitt investigators. Moffitt’s NCI funding increased slightly to $28.7M, with the majority of funding increases coming from other NIH, Department of Defense and other peer-reviewed sponsors, indicating a healthy, sustainable, and diversified funding portfolio.

UF Health Cancer Center

In the 2025 reporting period, UF Health investigators conducted 201 peer-reviewed research projects totaling $44.53M in awards. While this represents a 10% decrease from the previous year, the decline reflects the natural variability in the research funding cycle, including the conclusion of several large grants and faculty transitions.

Notably, NCI funding accounted for $17.97M in annual direct costs—over 40% of UF Health’s total peer-reviewed research portfolio—underscoring the continued strength of our cancer research enterprise.

UM Sylvester Comprehensive Cancer Center

UM Sylvester’s annual direct cost NCI-funding base has also grown from $14.5M to $21.1M between Reporting Period 2023 and Reporting Period 2025, while the total peer-reviewed funding was maintained at $42.2M, despite national reductions in federal grant programs. In FY 2024 alone, UM Sylvester investigators were awarded 44 new cancer-related grants and contracts. Of these grants, seven were received by UM Sylvester faculty in leadership. UM Sylvester also reported continued success with multi-PI grants during the reporting period with award funding increasing 12% from $18.4M in Reporting Period 2023 to $20.6M in Reporting Period
2025.

Mayo Clinic Comprehensive Cancer Center in Florida

In 2025, Mayo Clinic in Florida demonstrated substantial growth in its research portfolio, with total peer-reviewed awards reaching $13.9 million, representing a 60.5% increase since 2022. This growth supports 72 active research projects, marking a 38.5% increase in investigator-led initiatives. NCI funding also increased by 35.7%, with awards totaling $5.7 million. Much of this growth reflects expanded support from the NIH and other peer reviewed sponsors, highlighting Mayo Clinic in Florida’s robust, diversified, and sustainable research enterprise.

Peer-reviewed publications

Investigators at all four cancer centers remain highly productive, having published 7,046 peer-reviewed articles combined between 2022 and 2024 with 301 of the articles having at least one collaboration between Moffitt, UF Health, UM Sylvester, and/or Mayo Clinic in Florida researchers (see Collaborations section for more details).

Moffitt Cancer Center

Researchers at Moffitt published 2,514 peer-reviewed articles over the last three years with 27% appearing in high impact journals such as Nature, Science, Cancer Cell, and the New England Journal of Medicine. The average impact factor across this period was 11.484, which has remarkably increased by 60% from the last report. Its membership remains highly collaborative with 26% of articles having intra-programmatic collaborations and 21% having inter-programmatic collaborations.

UF Health Cancer Center

UF Health Cancer Center

UF Health researchers published a total of 1,554 peer-reviewed articles since 2023. Of the total publications, 28% were intra-programmatic, 14% were inter-programmatic and 75% of all publications were inter-institutional that included 181 collaborative publications with researchers at Moffitt and UM Sylvester.

UM Sylvester Comprehensive Cancer Center

UM Sylvester investigators published a total of 1,930 peer-reviewed cancer relevant journal articles from CY2022 to CY2024; 482 of the publications are published in journals with an impact factor greater than 10 and represent a high degree of collaboration among UM Sylvester’s investigators. The percentage of publications between UM Sylvester Research Programs (inter-programmatic publications) across the three-year period was 23% while collaboration within Research Programs (intra-programmatic publications) was 29%. Inter-institutional collaboration (with other NCI centers) accounted for 62% of the articles. Sylvester collaborated with Moffitt, UF Health, and/or Mayo on 154 of these 1,930 publications.

Mayo Clinic Comprehensive Cancer Center in Florida

Mayo Clinic in Florida conducts and disseminates high-quality peer-reviewed research in numerous cancer focused areas. The scope of research activities includes basic, translational, clinical, population sciences, healthcare delivery science, and cancer control and prevention. Mayo Clinic in Florida is a robust and dynamic enterprise, comprising 55 distinguished members across 16 departments, 6 interdisciplinary research programs, and 6 shared resources. From 2022 to 2024, members published 1,048 peer-reviewed manuscripts, with 20% appearing in journals with an Impact Factor>10. The Membership is highly connected with 14% of publications being intra-collaborative, 13% being inter-collaborative, and 44% being external collaborations with other NCI Cancer Centers.

Reportable cases and interventional trials

Over the last three Reporting Periods, the FACCA centers served 79,480 new patients (analytic cases) combined (Fig. 4) and accrued 31,942 patients to investigator-initiated interventional trials. The accrual is remarkably over 40% of the new cases. (Fig. 5).

Moffitt Cancer Center

Moffitt primarily serves Floridians with almost 97% of its patients coming from all 67 counties in the state and is reflected in the 30,060 cumulative new analytic cases reported over the last three reporting periods. Further, the demand for care at Moffitt reflects the numerous opportunities to participate in cutting edge clinical studies and experience the resulting superior outcomes. As such, Moffitt accrued 6,856 individuals to investigator-initiated interventional studies since the last report, which encompassed protocols of all types including treatment, screening, and prevention. Moffitt also continues to grow its reach and provided care for 11,553 admissions; 668,385 outpatient
visits; 13,961 surgeries; 30,903 new patients (non-analytic + analytic cases), and 1,088 in the most recently completed fiscal year (FY24). Additionally, Moffitt continued to reach the community with 314 total health education events.

UF Health Cancer Center

Since the prior report, the UF Health Cancer Center (UFHCC) enrolled a total of 964 patients to interventional treatment trials, with annual accruals rising from 260 in 2022 to 315 in 2023 and reaching 389 in 2024, a 50% increase over the three-year period. Enrollment to IITs totaled 10,132 across the same period, including a peak in 2022 driven by a large, multi-year cancer prevention study. Following its completion, IIT enrollment declined to 2,491 in 2023 and 496 in 2024, a temporary dip UFHCC is actively addressing through a new wave of IIT activations. These include a trial evaluating modernized at-home care instructions to improve treatment compliance and reduce complications (PI: Hitchcock), a tobacco cessation intervention for cancer survivors and caregivers (PI: LeLaurin), and a lung cancer screening uptake initiative (PI: Wollney). The center’s commitment to advancing investigator-led treatment studies is further demonstrated through targeted pilot awards aimed at addressing critical gaps in women’s cancers and surgical innovation.

Funded projects over the past three years include a novel technique to improve lymphatic drainage following mastectomy (PI: Spiguel), an innovative cavity-marking method to optimize post-resection radiation planning (PI: Spiguel), a suture-less partial nephrectomy approach for renal masses (PI: O’Malley), and a smoking cessation
intervention tailored to women undergoing breast reconstruction (PI: Fieber). As of 2024, 70% of all treatment enrollments and 77% of all interventional accruals were to IITs, underscoring UFHCC’s continued investment in homegrown, practice-informing research.

UM Sylvester Comprehensive Cancer Center

Between Reporting Period 2023 and Reporting Period 2025, UM Sylvester treated 19,187 newly diagnosed cancer patients (analytic cases) and significantly expanded access to cutting edge research. Enrollment in investigator-initiated interventional clinical trials grew by 175%, from 389 patients in Reporting Period 2023 to 1,070 in Reporting Period 2025—a record total of 2,190 patients across the 3-year period, representing 11% of newly diagnosed cases. As part of UM Sylvester’s 2024-2028 Strategic Plan, the Center is focused on expanding trial access across its network, with eight regional locations now offering open protocols: Aventura, Coral Springs, Doral, Deerfield Beach, Hollywood, Kendall, Lennar, and Plantation. As of December 31, 2024, 68% of all Sylvester’s open interventional protocols were available at one or more network location, expanding access to lifesaving clinical trials across South Florida. Enrollment to Phase I clinical trials, the first step in evaluating new cancer therapies, also increased during this period (from 111 to 251) reflecting UM Sylvester’s growing role of advancing innovative treatment options.

Mayo Clinic Comprehensive Cancer Center in Florida

Mayo Clinic Comprehensive Cancer Center in Florida Mayo Clinic in Florida cared for 11,795 newly diagnosed cancer patients (Cancer Registry analytic cases) and enrolled 12,801 participants in investigator-initiated interventional clinical trials (IITs). As an integral part of a multidisciplinary and patient-centered care model, Mayo Clinic in Florida delivers comprehensive cancer care across 50 medical and surgical specialties and subspecialties. This work is supported by a dedicated workforce of 9,219 professionals, including 7,996 allied health staff and 1,223 physicians, scientists, residents, and fellows.

Together, they advance Mayo Clinic’s mission to transform cancer care through excellence in clinical practice, groundbreaking research, and world-class education.

Cancer Mortality Rates

Each Center tracks mortality rates within their geographic catchment areas and how they compare with those in the State of Florida. Please see Appendix A for detailed mortality rate information for each Center.

Florida Cancer Center Collaborations

FACCA Pilot Projects

Since its inception in 2015, the original three centers have cumulatively invested $3.2M and have awarded 23 collaborative pilot grants to 58 researchers across the four cancer centers. With Mayo joining in the program in 2023, additional investment is planned in coming years. The FACCA Pilot Program collects outcomes for up to 5 years past the project period of the award. Thus, this report focuses on the outcomes of the last 5 years (pilot cycles 2019 – 2022), which consists of 9 pilot awards and represents a total investment of $1.35M by Moffitt, UF Health, and UM Sylvester. The investigators of these projects have been highly productive, remarkably returning $19.5M in extramural funding with 88% of awards stemming from peer-reviewed sponsors. Further, these pilot awards have resulted in 20 peer-reviewed publications and 2 patent applications. A summary of each center’s return on investment is provided below.

Moffitt Cancer Center

Since 2015, Moffitt invested $1M in funds across 17 pilot awards to 18 distinct Moffitt investigators. Of these awards, 12% were collaborations between UF Health and Moffitt, 35% between Moffitt and UM Sylvester, and 53% were collaborations between all three centers.

Over the last 5 years, Moffitt invested $450,000 in funds across 7 pilot awards to 7 Moffitt investigators. Of these awards, 57% were collaborations between Moffitt and UM Sylvester and 43% were collaborations between all three centers. These pilot awards returned $9.4M in extramural funding (80% peer-reviewed) and 11 peer-reviewed publications.

UF Health Cancer Center

Since 2015, UF Health has invested $1M in funds across 17 pilot awards to 17 distinct UF Health investigators. Of these awards, 12% were collaborations between UF Health and Moffitt, 35% between UF Health and UM Sylvester, and 53% were collaborations between all three centers.

Over the last 5 years, UF Health invested $350,000 across 5 pilot awards to 5 UF Health investigators. Of these awards, 40% were collaborations between UF Health and UM Sylvester, and 60% were collaborations between all three centers. These pilot awards returned $16.3M in extramural funding (100% peer-reviewed) and 16 peer reviewed publications. Newly awarded, peer reviewed extramural grants where UF Health is the prime institution include NCI U01CA274970 (MPIs: Krieger & Carrasquillo), NIGMS RM1GM139690 (MPIs: Moldawer, Efron, Kladde, & Mathews), and DoD USAMRA HT94252410275 (PI; Clanton).

UM Sylvester Comprehensive Cancer Center

Since 2015, UM Sylvester invested $1.2M in funds across 21 pilot awards to 23 distinct UM Sylvester investigators. Of these awards, 28% were collaborations between UM Sylvester and Moffitt, 29% between UF Health and UM Sylvester, and 43% were collaborations between all three centers.

Of the 9 pilot awards that were active between Reporting Periods 2023 and 2025, these projects returned $19.5M in extramural funding (88% peer-reviewed), 20 peer-reviewed publications, and 2 patent applications. Of the $19.5M in extramural funding returned, $3.4M was received by UM Sylvester as the prime institution, highlighting a 6:1 return on investment.

From 2022-2024, UM Sylvester researchers partnered with colleagues at UF Health and Moffitt on three collaborative research projects funded through the FACCA pilot funding mechanism—advancing Sylvester’s strategic goals to promote cross-institutional collaboration, drive translational science, and make progress on highly prevalent cancers, including those with disparities in treatment outcomes across Florida. The projects funded during this period include: Establishing a Multi-site HIV Oncology Research Program in Florida (Neha Goel and Anna Coghill (Moffitt)); Target antigen and T cell exhaustion impact outcomes after CAR 19 and postCAR relapse (Jay Spiegel and Michael Jain (Moffitt)), and; Trends and disparities in cervical cancer screening uptake and follow-up among women in Florida (Matthew Schlumbrecht, Jessica Islam (Moffitt)), and Stephanie Staras (UF Health)). The full impact of these pilot awards will continue to develop over time, as research outcomes often take several years to emerge. A detailed return on investment for all UM Sylvester funded projects is available in Appendix B.

Mayo Clinic Comprehensive Cancer Center in Florida

As a new member of the Alliance, Mayo Clinic in Florida has not yet had the opportunity to join the pilot project program but is committed to actively participating over the next several years. Mayo Clinic in Florida is particularly looking forward to opportunities to partner with FACCA members to accelerate capabilities to avail cancer care and research to Floridians in rural and underserved areas across the state.

Extramural Collaborations

Collaboration between the FACCA centers emanate from, and extend beyond, the pilot program and reflect the collaborative cultures at all four institutions. Over the last three years (CY22, CY23, and CY24), the centers have generated 301 unique peer-reviewed publications that have at least one collaboration between the centers and 14 unique articles where all four centers have collaborated. Additionally, investigators from the four institutions have collaborated on extramural peer-reviewed research projects. Center specific details are described below.

Moffitt Cancer Center

Over the last three reporting periods, Moffitt investigators published 2,514 peer-reviewed articles. Of those, 380 (15.1%) unique publications had collaborations with researchers from at least once of the other FACCA centers (Table 1). Of those articles, Moffitt collaborated on 148 articles with a UF Health investigator; 138 articles with a UM Sylvester investigator; 80 with a Mayo Clinic investigator; and 14 with at least 1 investigator from all three other centers.

Moffitt researchers collaborate with investigators from UF Health, UM Sylvester, and Mayo Clinic on 26 exciting, funded research projects. A summary of active (as of 4/30/2025) Moffitt collaborative awards and subcontracts that involve FACCA centers are presented in Table 2. For example, Moffitt’s Dr. Conor Lynch is collaborating with UM Sylvester’s Dr. Kerry Burnstein on a mathematical approach to treatment of metastatic prostate cancer to the bone. As another example, Moffitt’s Dr. Keiran Smalley works with UF Health’s Dr. Jonathan Licht and UM Sylvester’s Dr. Zelia Correa in a longstanding collaboration to understand the underlying epigenetics of uveal melanoma liver metastasis.

UF Health Cancer Center

Of the more than 1,537 peer-reviewed articles published by UF Health investigators, 139 have collaborations with researchers from at least one of the three other FACCA centers (Table 3). Of these collaborative interinstitutional publications, 14% were with UM Sylvester researchers, 45% were with Moffitt researchers, 46% were with Mayo researchers, and 15% involved researchers at two or more centers.

UF Health investigators collaborated with researchers from Moffitt and UM Sylvester on cutting-edge funded research projects since the last report that developed outside of the FACCA pilot program. A summary of collaborative awards based at UF Health that involve collaborations with FACCA centers as demonstrated through a subcontract is presented in Table 4. For example, UF Health’s Dr. Matthew Disney works with Moffitt’s Dr. John Cleveland in a long-standing collaboration to understand and develop methods for targeted degradation of RNAs using small molecules for the treatment of cancer in an R01 research project funded from the NCI. UF Health’s Dr. Benjamin Lok is collaborating on an MPI U01 led by Dr. Janice Krieger at Mayo Clinic in Florida and UM Sylvester’s Dr. Olveen Carrasquillo that is investigating the use of precision recruitment of underrepresented individuals onto clinical trials to promote cancer health equity across Florida populations. Finally, UF Health’s Drs. Weizhou Zhang and Guangrong Zheng are collaborating with Moffitt’s Dr. Kieran Smalley to establish a new therapeutic target for melanoma.

UM Sylvester Comprehensive Cancer Center

During the reporting period, UM Sylvester researchers published a total of 1,930 peer-reviewed publications, of which 154 were collaborators at Moffitt, UF Health, and Mayo. Of these collaborative inter-institutional publications, 20% were with UF researchers, 81% were with Moffitt researchers, and 11% were with Mayo researchers. Table 5 summarizes the publications between CY2022 and CY2024.

UM Sylvester collaborated with researchers from Moffitt and UF Health on several innovative peer-reviewed grant awards that formed within and outside of the FACCA pilot program. A summary of these awards as demonstrated by either an inflowing or outflowing subcontract is presented in Table 6. For example, UM Sylvester’s Dr. Zelia Correa collaborates with Moffitt’s Dr. Keiran Smally and UF Health’s Dr. Jonathan Licht on an R01 NCI-funded research project focused on uncovering how mutant Gαq signaling and BAP1 loss drive liver metastasis in uveal melanoma by altering tumor cell states and interactions with the liver microenvironment, with the goal of identifying new therapeutic strategies targeting these mechanisms. Additionally, UM Sylvester’s Dr. Tracy Crane collaborates with Moffitt’s Dr. Damon Vidrine on a James and Esther King Biomedical Research Program-funded project aiming to develop a statewide mHealth (mobile health) infrastructure to support tobacco-related research in cancer care and testing its utility through three demonstration smoking cessation projects across Florida.

Mayo Clinic Comprehensive Cancer Center in Florida

During the reporting period, investigators from Mayo Clinic in Florida authored a total of 1,048 peer-reviewed manuscripts, reflecting the depth and breadth of the Center’s research enterprise. Of these, 114 publications were the result of collaborative efforts with researchers from Moffitt, UF Health, and UM Sylvester. Notably, 82% of these collaborations were with Moffitt, 29% with UM Sylvester, and 1% with UF Health. This robust collaborative engagement underscores Mayo Clinic’s commitment to advancing cancer research through strategic partnerships across Florida’s leading academic cancer centers. A detailed summary of these inter-institutional publications from CY2022
through CY2024 is provided in Table 7.

Mayo Clinic in Florida continues to demonstrate its leadership in advancing collaborative, high-impact cancer research across the state through strategic partnerships with other Florida Academic Cancer Center Alliance (FACCA) institutions that maybe seen in Table 8. Several innovative, peer-reviewed, and externally funded research projects have emerged during the reporting period, underscoring Mayo Clinic in Florida’s commitment to fostering statewide collaborations that drive scientific discovery and promote cancer health equity. Among these efforts, Mayo Clinic in Florida serves as a lead partner on an NCI-funded U01 project focused on precision clinical trial recruitment to advance cancer health equity, working alongside collaborators from UF Health and UM Sylvester. Additional partnerships include DOD funded research addressing chemotherapy-related cardiomyopathy in women, as well as the development of novel vaccines to prevent progression of triple-negative breast cancer. Mayo Clinic in Florida is also engaged in efforts to improve cancer literacy and screening awareness among incarcerated populations through a Radiation Oncology Institute-funded initiative with UF Health. Complementing these activities are NIH-funded collaborations targeting chemotherapy-related heart failure, glioblastoma progression, and cancer care for underserved populations across Florida.

FACCA Collaborative Meetings

The four centers regularly collaborate through recurring meetings, conferences, and retreats, which facilitates ongoing and new partnerships among the research communities across the centers. This level of collaboration demonstrates state-wide progress in addressing the needs of Florida citizens and develops a destination for medical tourism for cancer patients.

Since the last report, UM Sylvester hosted a FACCA retreat in March 2023 and UF Health hosted a retreat in April 2024 (Fig. 6). The FACCA retreat serves as a vital forum for fostering collaboration among Florida’s cancer centers, bringing together researchers to share knowledge, spark new partnerships, and align efforts around innovative, high-impact cancer research. This annual event strengthens the statewide cancer research ecosystem, accelerates progress toward shared scientific goals, and provides a forum to share best practices and ultimately impact the delivery of patient care. The next retreat will be hosted by Moffitt and is being planned for Fall of 2025.

Table 9 illustrates the active work among the centers to ensure opportunities are available to foster inter-institutional collaborations. In addition to the retreats and Director’s meetings, the research administration teams from each center meet monthly to discuss ongoing and emergent items related to FACCA. Detailed retreat agendas are provided in Appendix C.

Summary

The State of Florida, as well as each participating cancer center, continue to realize transformative benefits from the Casey DeSantis Cancer Research Program. This critical investment has provided vital resources for reaching the program’s overarching goal of achieving and maintaining four NCI designated centers, most notably the designation of UF Health in 2023 and the addition of Mayo Clinic Florida in 2024. By establishing a robust, statewide network of cancer innovation hubs, the program amplifies each center’s strengths to drive breakthrough discovers, expand access to cutting-edge therapies, and foster high-impact scientific collaboration.

Through sustained support, Florida is poised to lead the nation in cancer research, prevention, and care, ultimately leading to better cancer care and improved outcomes for patients throughout Florida. With annual reporting moving forward, FACCA will continue to demonstrate impact and success, bringing the best and brightest to Florida to lead the nation in cancer research, prevention, and translation and improve the health of all residents across the state.